Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 3/20 | 0.32 |
| ▸ | DRD2 | P14416 | 3/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4130358 | 0.72 | TDP1 (0.50) | KDM4ENPC1CYP1A2RAB9AL3MBTL1 | |
| SCHEMBL21975337 | 0.68 | ASIC3 (0.46) | HTR1ANPC1CYP1A2CYP2C19RAB9A | |
| SCHEMBL22068582 | 0.66 | ASIC3 (0.44) | HTR1AKDM4ENPC1 | |
| SCHEMBL24696102 | 0.65 | NOS3 (0.30) | — | |
| SCHEMBL29437822 | 0.65 | VNN1 (0.46) | — | |
| SCHEMBL24794924 | 0.64 | CHRNB2 (0.44) | NPC1RAB9A | |
| SCHEMBL9485195 | 0.64 | ALDH1A1 (0.52) | HTR1ADRD2 | |
| SCHEMBL22736638 | 0.61 | MEN1 (0.55) | HTR1ADRD2KDM4ERAB9AL3MBTL1 | |
| SCHEMBL23033831 | 0.61 | MAPT (0.44) | KDM4EL3MBTL1 | |
| SCHEMBL11983573 | 0.61 | CCR1 (0.53) | KDM4ECYP2C19L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170155057-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-06-01 | — | — | US | disclosed |
| US-20170155057-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170155057-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, OCIAD1, CCNT1 | IDO1 2418/4885IDO2 3174/4885HTR1A 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.